Roibeard O’hEineachain
Published: Monday, September 28, 2020

David B Granet MD
FACS FAAP FAAO
The introduction and FDA approval of the monoclonal antibody teprotumumab (Tepezza, Horizon Therapeutics) heralds a new era in the treatment of thyroid eye disease, said David B Granet, MD FACS FAAP FAAO, Shiley Eye Center, University of California, San Diego, US.
“We used to say that in the future thyroid eye disease will be stopped with medication and not the scalpel. The future has arrived,” Dr Granet told the 2020 WSPOS Virtual Meeting.
The human monoclonal antibody was approved for use in the United States in January 2020. It binds to the insulin-like growth factor 1 receptor (IGF-1R) and by doing so also inhibits thyroid-stimulating hormone (TSH). In this way it inhibits the inflammatory cascade thereby reducing oedema and glycosaminoglycan production. It is administered intravenously at a dosage of 20mg/kg in eight cyles over 24 weeks, Dr Granet noted.
The FDA approved teprotumumab based on two randomised controlled studies showing a greater than 2.0mm reduction in proptosis in 71% and 83% of patients receiving the monoclonal antibody, compared to 20% and 10% of control patients. Dr Granet presented two case studies, one with active disease and the other with chronic disease, whose eyes in both cases returned to their normal state after completing eight cycles of treatment.
“This is a game changer; however, there are side-effects and of course we have to pay attention to the teratogenicity of this in someone who might be pregnant. There may be relapses as well and it is expensive,” Dr Granet added.
Tags: thyroid eye disease
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Read more...
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Read more...
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Read more...
Supplement: ESCRS Clinical Trends Series: Presbyopia
Read more...
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
Read more...
New Award to Encourage Research into Sustainable Practices
Read more...
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Read more...
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Read more...
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
Read more...
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.
Read more...